Dolutegravir in late pregnancy: where to from here?

Lancet HIV. 2022 Aug;9(8):e522-e523. doi: 10.1016/S2352-3018(22)00193-X.
No abstract available

Publication types

  • Comment

MeSH terms

  • Female
  • HIV Infections* / drug therapy
  • HIV Integrase Inhibitors* / adverse effects
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Humans
  • Oxazines / therapeutic use
  • Piperazines
  • Pregnancy
  • Pyridones / therapeutic use

Substances

  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir